Neuren Pharmaceuticals Ltd
ASX:NEU
Intrinsic Value
The intrinsic value of one
NEU
stock under the Base Case scenario is
12.4
AUD.
Compared to the current market price of 18.73 AUD,
Neuren Pharmaceuticals Ltd
is
Overvalued by 34%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Neuren Pharmaceuticals Ltd.
Fundamental Analysis
Regulatory uncertainty surrounding Neuren’s lead candidate trofinetide—particularly in complex neurological indications—poses a significant risk, as any delays in approvals or unfavorable trial data could derail the company’s revenue timeline and shake investor confidence.
Trofinetide’s potential first-mover advantage in Rett syndrome offers a pathway to regulatory approval and commercial success, creating a strong, near-term revenue stream if upcoming data and launches proceed favorably.
Revenue & Expenses Breakdown
Neuren Pharmaceuticals Ltd
Balance Sheet Decomposition
Neuren Pharmaceuticals Ltd
| Current Assets | 320.2m |
| Cash & Short-Term Investments | 299.5m |
| Receivables | 20.7m |
| Non-Current Assets | 11m |
| PP&E | 25k |
| Other Non-Current Assets | 11m |
Free Cash Flow Analysis
Neuren Pharmaceuticals Ltd
| AUD | |
| Free Cash Flow | AUD |
Earnings Waterfall
Neuren Pharmaceuticals Ltd
|
Revenue
|
228.7m
AUD
|
|
Operating Expenses
|
-34.8m
AUD
|
|
Operating Income
|
193.9m
AUD
|
|
Other Expenses
|
-44.8m
AUD
|
|
Net Income
|
149.1m
AUD
|
NEU Profitability Score
Profitability Due Diligence
Neuren Pharmaceuticals Ltd's profitability score is 79/100. The higher the profitability score, the more profitable the company is.
Score
Neuren Pharmaceuticals Ltd's profitability score is 79/100. The higher the profitability score, the more profitable the company is.
NEU Solvency Score
Solvency Due Diligence
Neuren Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Neuren Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NEU Price Targets Summary
Neuren Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for
NEU
is 26.97 AUD
with a low forecast of 21.41 AUD and a high forecast of 33.6 AUD.
Dividends
Current shareholder yield for
NEU is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
NEU
stock under the Base Case scenario is
12.4
AUD.
Compared to the current market price of 18.73 AUD,
Neuren Pharmaceuticals Ltd
is
Overvalued by 34%.